Macrophages mediate kidney disease and are prominent in a mouse model (MRL-Fas lpr ) of lupus nephritis. Colony stimulating factor-1 (CSF-1) is the primary growth factor for macrophages, and CSF-1 deficiency protects MRL-Fas lpr mice from kidney disease and systemic illness. Whether this renoprotection derives from a reduction of macrophages and whether systemic CSF-1, as opposed to intrarenal CSF-1, promotes macrophage-dependent lupus nephritis remain unclear. Here, we found that increasing systemic CSF-1 hastened the onset of lupus nephritis in MRL-Fas lpr mice. Using mutant MRL-Fas lpr strains that express high, moderate, or no systemic CSF-1, we detected a much higher tempo of kidney disease in mice with the highest level of CSF-1. Furthermore, we uncovered a multistep CSF-1-dependent systemic mechanism central to lupus nephritis. CSF-1 heightened monocyte proliferation in the bone marrow (SSC low CD11b ϩ ), and these monocytes subsequently seeded the circulation. Systemic CSF-1 skewed the frequency of monocytes toward "inflammatory" (SSC low CD11b ϩ Ly6C high ) and activated populations that homed to sites of inflammation, resulting in a more rapid accumulation of intrarenal macrophages (CD11b ϩ CSF-1R ϩ or CD68 ϩ ) that induced apoptosis of tubular epithelial cells, damaging the kidney. In humans, we found increased levels of CSF-1 in the serum, urine, and kidneys of patients with lupus compared with healthy controls. Furthermore, serum and urine CSF-1 levels correlated with lupus activity, and intrarenal CSF-1 expression correlated with the histopathology activity index of lupus nephritis. Taken together, circulating CSF-1 is a potential therapeutic target for lupus nephritis.
ABSTRACT
Macrophages mediate kidney disease and are prominent in a mouse model (MRL-Fas lpr ) of lupus nephritis. Colony stimulating factor-1 (CSF-1) is the primary growth factor for macrophages, and CSF-1 deficiency protects MRL-Fas lpr mice from kidney disease and systemic illness. Whether this renoprotection derives from a reduction of macrophages and whether systemic CSF-1, as opposed to intrarenal CSF-1, promotes macrophage-dependent lupus nephritis remain unclear. Here, we found that increasing systemic CSF-1 hastened the onset of lupus nephritis in MRL-Fas lpr mice. Using mutant MRL-Fas lpr strains that express high, moderate, or no systemic CSF-1, we detected a much higher tempo of kidney disease in mice with the highest level of CSF-1. Furthermore, we uncovered a multistep CSF-1-dependent systemic mechanism central to lupus nephritis. CSF-1 heightened monocyte proliferation in the bone marrow (SSC low CD11b ϩ ), and these monocytes subsequently seeded the circulation. Systemic CSF-1 skewed the frequency of monocytes toward "inflammatory" (SSC low CD11b ϩ Ly6C high ) and activated populations that homed to sites of inflammation, resulting in a more rapid accumulation of intrarenal macrophages (CD11b ϩ CSF-1R ϩ or CD68 ϩ ) that induced apoptosis of tubular epithelial cells, damaging the kidney. In humans, we found increased levels of CSF-1 in the serum, urine, and kidneys of patients with lupus compared with healthy controls. Furthermore, serum and urine CSF-1 levels correlated with lupus activity, and intrarenal CSF-1 expression correlated with the histopathology activity index of lupus nephritis. Taken together, circulating CSF-1 is a potential therapeutic target for lupus nephritis. Identifying molecules that mediate experimental lupus nephritis may uncover therapeutic targets and biomarkers. MRL-Fas lpr mice develop a systemic autoimmune disease akin to human lupus nephritis and thus are a powerful tool to probe for molecules that regulate kidney disease in these patients. 1, 2 Kidney disease in MRL-Fas lpr mice is rapid, progressive, and predictable. 3 Moreover, the time frame is sufficiently slow to tease apart the pathogenesis, and sufficiently fast to be efficient. Thus, these mice are a powerful tool to probe for therapeutic targets and biomarkers in human lupus nephritis.
Macrophages (Mø) regulate kidney disease. 4 Mø originate from pluripotent stem cells in the bone marrow that differentiate into mature monocytes (Mo), which enter the blood stream 5, 6 and traffic to the kidney. Growing evidence implicates Mø as mediators of lupus nephritis because intrarenal Mø (CD68 ϩ , F4/80 ϩ ) increase with advancing disease in MRL-Fas lpr mice. 7 Mø require the colony stimulating factor-1 (CSF-1), their principle growth factor, to differentiate, survive, and multiply. 8 Our prior studies indicate that CSF-1 is central to lupus nephritis. Implanting cells generating CSF-1 into the kidney of MRL-Fas lpr mice incites local Mø-rich inflammation. 9, 10 Moreover, CSF-1-deficient mice (Csf1 op/op ;MRL-Fas lpr ) are protected from kidney disease and systemic illness. 11, 12 However, the Csf1 op/op ;MRLFas lpr mice are frail and have skeletal abnormalities and numerous other defects. [13] [14] [15] [16] Thus, it is possible that the effect of deleting CSF-1 on lupus in MRL-Fas lpr mice is, at least in part, not directly related to the reduction of Mø. Moreover, CSF-1-generating cells implanted into the kidney induce inflammation that is restricted to the area adjacent to the implant site. 9 Thus, the systemic effect of CSF-1 during the initiation and progression of Mø-dependent lupus nephritis remains unclear.
Understanding the effect of circulating and tissue CSF-1 expression is key to designing a therapeutic treatment. CSF-1 is expressed in the circulation and is upregulated in the kidney in MRL-Fas lpr mice with lupus nephritis. [17] [18] [19] Intrarenal CSF-1 expression occurs during inflammation and expression is largely limited to tubular epithelial cells (TECs). 20 Moreover, the rise in circulating CSF-1 precedes intrarenal CSF-1 expression and is bimodal in MRL-Fas lpr mice. CSF-1 is upregulated in neonates, declines to normal levels, and then progressively rises with advancing kidney disease in MRL-Fas lpr mice. 19 Moreover, an increase in CSF-1 in the circulation precedes overt kidney pathology in MRL-Fas lpr mice. 18, 19 However, it is not clear whether CSF-1 in the circulation, apart from intrarenal CSF-1, is central to the progression of lupus nephritis in MRL-Fas lpr mice. Therefore, we propose to test the hypothesis that systemic CSF-1 hastens the progression of Mø-rich lupus nephritis. Furthermore, we hypothesize that circulating CSF-1 increases the frequency of circulating Mo (SSC low CD11b ϩ ), which are more readily recruited to the kidney and, in turn, induce injury.
Finally, preclinical studies are a first step in identifying therapeutic targets and biomarkers for lupus nephritis and require validation in humans. Therefore, we propose to test the hypothesis that CSF-1 is upregulated in the circulation, urine, and kidneys of patients with active lupus nephritis. Figure 1A ) and tissues ( Figure 1B ) with advancing age and disease (1.5, 3.0, and 5.0 mo of age). The increase in CSF-1 in the TgC/ϩ;MRL-Fas lpr was, as anticipated, higher than in MRL-Fas lpr mice. By comparison, serum CSF-1 levels in age-matched MRL-ϩϩ and normal B6 mice remained unchanged (dotted line, Figure 1A) Figure  2B ). Taken together, increasing CSF-1 in MRL-Fas lpr mice in the circulation ( Figure 1A ) and kidney (primarily in TECs and to a lesser extent within glomeruli) ( Figure 2C ) hastens the tempo of kidney disease and shortens survival. ϩ in the kidney than WT mice ( Figure 3A ). In contrast, CD68 ϩ cells were rare in Csf1 op/op ;MRL-Fas lpr kidneys ( Figure 3A) . Furthermore, we detected an increase in the leukocyte populations of B220 ϩ (largely expressed by doublenegative T cells 22 ), CD4 ϩ , and CD8 ϩ known to accompany Mø that was proportional to the level of CSF-1 in nephritic MRLFas lpr mice (Supplement Figure 2) . Of note, the magnitude of double-stranded DNA antibodies (dsDNA Abs) did not rise along with increasing CSF-1 levels and the CSF-1-dependent increase in renal disease (Supplement Figure 3) Figure 3C ), but not in the blood ( Figure 3B2 , Supplement Figure 4B Ϫ "resident" subset characterized by CCR1-dependent recruitment to noninflamed tissues. 6, 23 To determine if an increased CSF-1 expression shifted the circulating Mo (SSC Figure 5 ). Of note, the resident Mo subset has recently been shown to patrol blood vessels and rapidly (1 to 2 h) invade tissues after an infection. 24 However, our studies focus on CSF-1-dependent events at later time points (24 6 Dependent on their milieu in the circulation, the Ly6C expression on Mo will be downregulated, resulting in an decreased recruitment to inflamed tissue. 6 We detected an increase in hematopoetic cells (CD45. Figure 7) , it is likely that most EGFP ϩ BM in the kidney reflects recruitment rather than proliferation. 6 CSF-1 directly activates Mø (CD68 ϩ ), 25 and these Mø, in turn, release mediators that induce TEC apoptosis in vitro. 26 sion in MRL-Fas lpr mice increases the number of Mo seeded from the BM into the circulation; shifts these Mo toward an inflammatory and activated phenotype; and, in turn, hastens the rise of activated Mø in the kidney that induces TEC apoptosis.
RESULTS

The
Circulating CSF-1, apart from Intrarenal CSF-1, Increases Mø in the Kidney
To determine whether a rise in circulating CSF-1 alone, apart from upregulated intrarenal CSF-1, contributes to the CSF-1-dependent increase in intrarenal Mø (CD45.1 ϩ CSF-1R ϩ ) in the kidney, we compared Csf1 op/op ;MRL-Fas lpr mice injected with CSF-1 versus PBS for 2 d (Supplement Figure  9) Figure 5A ). This suggests that increasing circulating CSF-1 enhances Mø accumulation in the kidney. Figure 5C ). Furthermore, we detected a considerable rise in the frequency and total number of Ly6C high CD11b ϩ inflammatory Mo in the circulation and Ly6C high F4/80 ϩ activated Mø (F4/80 ϩ ) in the kidney of CSF-1-versus PBS-treated mice ( Figure 5D ). Taken together, this suggests that elevation of circulating CSF-1 alone is responsible for increasing the number of Mo released from the BM into the circulation and for shifting the circulating Mo populations toward a Ly6C high activated Mo phenotype that is more readily recruited into the kidney.
CSF-1 is Expressed by TECs in Patients with Lupus Nephritis
To determine whether our findings in lupus nephritis in mice may be applicable to human lupus, we probed for CSF-1 expression in kidney sections in patients with lupus nephritis, in proteinuric patients with other kidney diseases (minimalchange and membranous GN), and in control patients (patient's characteristics; Table 1 ). Similar to the MRL-Fas lpr mice, CSF-1 is highly (nearly 50%) expressed by TECs in patients with lupus nephritis as compared with other kidney diseases and controls ( Figure 6A ). By comparison, CSF-1 is more robustly expressed in lupus nephritis as compared with other kidney diseases (minimal-change and membranous GN) with far fewer intrarenal leukocytes (CD68: 36 Ϯ 8 versus 10 Ϯ 3; CD3: 18 Ϯ 5 versus 4 Ϯ 1, respectively, n ϭ 10/group). Note CSF-1 expression is specific because we did not detect staining using a goat IgG control, and CSF-1 staining was blocked by BASIC RESEARCH www.jasn.org preabsorption of the anti-CSF-1 antibody ( Figure 6A ). To determine whether elevated CSF-1 expression by TECs correlates with the activity and chronicity of the lupus nephritis, we evaluated the histopathological activity index and chronicity index. 27, 28 We determined that the CSF-1 expression in TECs correlates with the activity index but not with the chronicity index ( Figure 6B ). Thus, TECs are the principle source of CSF-1 in human lupus nephritis and the level of CSF-1 expression is an index of disease activity. 
CSF-1 Is Increased in the Serum and Urine in Patients with Serologically Active Lupus Nephritis
To determine whether the pathologic effect of elevated systemic CSF-1 on lupus nephritis may be relevant in humans, we measured the concentrations of CSF-1 in serum and urine of patients with lupus nephritis, proteinuric patients with other kidney diseases (minimal-change and membranous GN), lupus patients without nephritis, and healthy controls. We detected a marked rise in CSF-1 in the serum and urine in patients with lupus nephritis, as compared with other kidney BASIC RESEARCH www.jasn.org diseases and healthy controls ( Figure 7A , Table 1 ). Moreover, CSF-1 was elevated in the serum, but not in the urine, in patients with lupus nephritis compared with patients with lupus without nephritis ( Figure 7A , Table 1 ). To determine whether CSF-1 expression correlated with disease activity in lupus, we evaluated serologic parameters and renal function. Lupus activity parameters included low levels of serum C3 and C4 and high levels of serum anti-dsDNA Ab. We determined that circulating CSF-1 concentrations correlated with the low levels of C3 and C4 and elevated dsDNA Ab levels in the sera ( Figure  7B ). By comparison, we did not detect CSF-1 in the serum of healthy individuals. Furthermore, CSF-1 levels in the urine correlated with low, but not high, proteinuria/creatinine ratios in patients with serologically active lupus nephritis. This finding most likely reflects an increased loss of TECs that generate CSF-1 with advancing loss of renal function ( Figure 7C1 ). Of note, CSF-1 was higher in patients with active lupus nephritis compared with those in remission ( Figure 7C2 ). Taken together, a rise of CSF-1 expression in TECs and elevated CSF-1 in the serum and urine are indicators of active lupus nephritis.
DISCUSSION
CSF-1 may be a "master switch" regulating the multiorgan disease characteristic of MRL-Fas lpr mice. The concept that CSF-1 expression in the circulation and tissues promotes lupus is in keeping with our prior studies. 17, 29, 30 Using the CSF-1 transgenic MRL-Fas lpr line that promotes lupus nephritis we have used in the study presented here, we previously detected a more rapid onset of cutaneous disease (discoid lupus) compared with WT mice. 25 Moreover, sunlight exposure induces CSF-1 in keratinocytes in the epidermis that spills over into the circulation and, in turn, leads to the recruitment and activation of Mø (F4/80 ϩ CD68 ϩ ) in the skin. Thus, CSF-1 sets in motion Mø-mediated events leading to the destruction of keratinocytes and discoid lupus. 25 Because disease in MRL-Fas lpr is a multiorgan disease involving kidney, skin, and other tissues, 31 many tissues may contribute and respond to increasing circulating CSF-1 levels. Because our study indicates that circulating CSF-1 is instrumental in mediating renal injury, we speculate that CSF-1 generated within the kidney that is released into the circulation has an effect on cutaneous disease and other tissues, and vice versa. Thus, systemic CSF-1 expression may regulate multitissue injury in lupus.
We now report that CSF-1 regulates the generation of inflammatory Ly6C high Mo (SSC low CD11b high ). 23 Evidence suggests that inflamed tissues increase circulating CSF-1 and thereby stimulate the production of Mo (SSC low CD11b high ) in the BM and their subsequent release into the circulation. 6 When this is substantial, there is a skewing of the Mo population toward a higher frequency of Ly6C high cells. Our data suggest that this skewing toward circulating Ly6C high cells is CSF-1-dependent. This is based on the CSF-1-dependent increase in the immature Ly6C high Mo proliferation and the rise in circulating Ly6C high Mo that are more readily recruited to the kidney. The MRL-Fas lpr kidney may be self-destructive. Because renal TECs are a rich source of CSF-1 during inflammation, 20 CSF-1 originating from the kidney may, in part, account for the rise in circulating CSF-1 that drives Mø Figure 7 . CSF-1 is elevated in urine and serum of patients with lupus nephritis and correlates with disease activity. (A) CSF-1 levels in serum and urine are elevated in patients with lupus nephritis compared with other kidney disease and healthy controls (ELISA). CSF-1 is elevated in the serum, but not urine, of lupus patients with nephritis compared with those without nephritis. (B) Serum CSF-1 levels of patients with lupus nephritis correlate with serologically active lupus (low C3/C4, high anti-dsDNA Ab). (C) Urine CSF-1 levels in patients with lupus nephritis correlates with low, but not high, proteinuria/creatinine ratios. The criteria for proteinuria/creatinine ratios is high Ͼ1000 mg/24 h; and low Ͻ1000 mg/24 h). CSF-1 in the urine is elevated in patients with active lupus compared with those in remission (proteinuria Ͻ300 mg/24 h, creatinine Ͻ1.3 mg/dl). The clinical data and histopathology type of GN of the patient collective are summarized in Table 1 . Values are the mean Ϯ SEM.
(CD68 ϩ ) to become activated and destroy the kidney. 25, 26 On the other hand, CSF-1 is increased in the circulation in neonates, well in advance of renal injury in MRL-Fas lpr mice. 19 Thus, it is possible that a circulating CSF-1-dependent mechanism leads to amplifying intrarenal CSF-1. Regardless, our findings indicate that CSF-1 is the conduit between the circulation and tissue that regulates the destiny of Mo and, in turn, inflammation in MRL-Fas lpr mice. CSF-1 levels in the serum and urine may be a biomarker for active lupus nephritis. This is consistent with a prior finding indicating that urinary CSF-1 (also known as M-CSF), regulated upon activation, normal T cell expressed and secreted protein, and monocyte chemoattractant protein-1 are increased during renal flares in patients with lupus. 32 Our data agree with a report indicating that elevated CSF-1 in the sera of patients with lupus, including those with nephritis, correlates with disease activity. 33 However, our findings extend prior reports because our data indicate that urinary and serum CSF-1 and CSF-1 levels in the kidney correlate with active lupus. Although our findings indicate that low serum C3/C4, an index of active lupus, have a high correlation with increasing serum CSF-1 concentrations, the correlation of high serum dsDNA Ab, another indicator of active lupus, is less impressive. This may be related to the extreme variability between dsDNA Ab commercial kits (10 kits tested, unpublished data). It is worth noting that urine CSF-1 correlates with moderate proteinuria (Ͼ1000 mg/24h), but not higher urinary protein levels. This is in keeping with the generation of CSF-1 at the onset of inflammation and the destruction of TECs, the major source of CSF-1, during persistent inflammation. Consistent with this concept, CSF-1 levels in TECs do not correlate with increasing histopathologic chronicity. Although urine and serum CSF-1 may be a biomarker for active lupus, it is unlikely that it is unique for lupus nephritis because CSF-1 is upregulated in the kidney after other forms of renal injury. For example, CSF-1 is expressed in TECs and to a lesser extent in glomeruli after acute kidney injury (after ischemia/reperfusion in mice and in patients with loss of renal function and tubular pathology postengraftment 34 ). Future studies will determine whether CSF-1 is a biomarker and therapeutic target for other human Mø-dependent kidney diseases. 35 CSF-1 expression during lupus nephritis is primarily within TECs, because expression in glomeruli is far less abundant. This is at odds with a prior report pinpointing the expression of CSF-1 in humans exclusively to glomeruli. 36 This may be related to the method of detecting CSF-1. For example, our prior findings in MRL-Fas lpr mice indicated that CSF-1 is expressed by TECs and mesangial cells using antibody detection, 17 whereas in this study we localize CSF-1 in TECs, mesangial cells, and podocytes by morphologic criteria and using mice expressing a CSF-1 reporter gene. However, pinpointing the precise cell types expressing CSF-1 during each stage of progressive lupus will require a more comprehensive analysis. Nevertheless, our findings indicate that CSF-1 expression in the kidney correlates with the histopathology activity index for lupus nephritis. However, to more fully explore CSF-1 as a biomarker for lupus nephritis, follow-up studies will correlate the pathology findings with the clinical disease activity score (SLEDAI) for each patient and determine whether serum and urine CSF-1 levels longitudinally track with the progression of lupus nephritis.
Understanding the effect of circulating versus tissue CSF-1 has profound therapeutic implications. We have compelling evidence that CSF-1 in the circulation alone enhances Mø-dependent lupus nephritis in MRL-Fas lpr mice. Injecting CSF-1 stimulates the proliferation of Mo (SSC low CD11b high ) in the BM, which subsequently leads to a rise in circulating Mo populations, which in turn are more readily recruited to the kidney and induce injury. This is consistent with a study in which injecting CSF-1 accelerates the intrarenal accumulation of Mø and proteinuria in LPS-treated nonlupus susceptible mice. 37 Within this context, our human translational findings indicate that the rise in circulating CSF-1 in these patients with lupus nephritis is not only a biomarker of disease activity but is instrumental in mediating lupus nephritis. This suggests that strategies to diminish circulating CSF-1 will halt escalating lupus nephritis in humans. Thus, purging CSF-1 from the circulation may tilt the balance of Mo back to a more mature population that is not readily recruited to tissues. Taken together, circulating CSF-1 is a potential therapeutic target and may be an attractive biomarker for lupus. 
CSF-1 ELISA
We measured mouse CSF-1 levels in the serum, urine, and tissue homogenates using an ELISA method. 25 Undiluted serum and urine samples were analyzed directly. The tissues used for homogenates were from mice perfused with PBS through the heart to flush out CSF-1 in the circulation. Briefly, we homogenized tissue samples using a MixMill 300 (Qiagen, Valencia, CA). Samples were spinned down and the supernatant fraction of the homogenates was used for the ELISA. 39 We determined the protein concentration of each sample (supernatant of homogenate) using the BCA Protein Assay Kit (PIERCE, Rockford, IL) and evaluated 200 g of protein per tissue sample. To detect CSF-1 in human serum and urine, we used a human CSF-1 ELISA kit according to the manufacturer's instructions. The ELISA antibodies and reagents were purchased from BD Bioscience (San Jose, CA).
Renal Histopathology
We fixed kidneys in 10% neutral buffered formalin for 24 h and stained paraffin sections (4 m) with periodic acid-Schiff reagent. We evaluated kidney pathology as described previously. 40 . We scored 20 gcs/kidney. Interstitial/tubular pathology was assessed semiquantitatively on a scale of 0 to 3 in 10 randomly selected high-power fields. We determined the largest and average number of infiltrates and damaged tubules and adjusted the grading system accordingly: 0 ϭ normal, 1 ϭ mild, 2 ϭ moderate, 3 ϭ severe. Perivascular cell accumulation was determined semiquantitatively by scoring the number of cell layers surrounding most vessel walls (score: 0 ϭ none, 1 ϭ Ͻ5 cell layers, 2 ϭ 5 to 10 cell layers, 3 ϭ Ͼ10 cell layers).
Renal Function
We measured BUN, creatinine, and albuminuria as described previously. 41 
Splenomegaly/Lymphadenopathy
Splenomegaly and lymph node weight were determined at the time of sacrifice by comparing the ratios of the tissue to body weight.
Immunostaining
Mouse Tissue.
Kidney tissue was processed and stained for the presence of CD68, CD4, CD8, B220, and anticleaved caspase-3 antibody (Asp175) (CellSignaling, Danvers, MA), as described previously for the kidney. 41 To identify ␤-galactosidase encoded by lacZ (CSF-1 expression), we treated frozen kidney sections as described previously. 20 
Human Tissue.
We deparaffinized and rehydrated serial sections (4 m). Antigen retrieval was performed by immersion in citrate buffer followed by blocking endogenous peroxidase activity and nonspecific binding of avidin and biotin as described previously. 41 We incubated these sections with a primary antibody, goat anti-human CSF-1 antibody (N-16; Santa Cruz, CA), and we detected the primary antibody by incubation with biotinylated rabbit anti-goat Ab followed by development with 3Ј3-diaminobenzidine (Vector; Burlingame, CA). We verified staining specificity by replacing the primary antibody with goat IgG (eBioscience, San Diego, CA) and by preabsorbing with peptide for CSF-1 antibody (Santa Cruz). We determined the percentage of positive TECs in ten randomly selected high-power fields.
Flow Cytometry
We prepared and stained single-cell suspensions from kidneys, blood leukocytes, and BM Mo as described previously. 42 We collected 0.5 ϫ 10 6 to 1.0 ϫ 10 6 total kidney cells and 0.5 ϫ 10 5 to 1.0 ϫ 10 5 blood leukocytes/BM Mo using a FACSCalibur (Becton Dickinson, San Jose, CA) and analyzed the data using Flowjo software (Tree Star, Palo Alto, CA). The BM Mo and circulating Mo were characterized by gating on the SSC low CD11b high population. 6 
Antibodies
We used the following antibodies from eBioscience (San Diego, CA) for FACS analysis: FITC-conjugated anti-CD4 (L3T4), anti-CD8 (53 to 6.7), and anti-CD11b (M1/70) band anti-CD45.2 (104); phycoerythrin (PE)-conjugated anti-CD4, anti-CD45.2, anti-CD69 (H1.2F3), and anti-CD86 (GL1); PE-Cy5-conjugated anti-CD8; and allophycocyanin-conjugated anti-CD4, anti-CD45.2, and anti-F4/80 (BM8). We used FITC-and allophycocyanin-conjugated anti-CD68 antibody (FA11) and PE-conjugated Ly6C (Serotec, Oxford, United Kingdom), purified CX 3 CR 1 (2A9-1; MBL, Woburn, MA),and purified rabbit anti-mouse CCR2 (NovusBiologicals). For the secondary PE-or allophyocyanin-conjugated Ab, we used goat-anti-rabbit from Jackson ImmunoResearch Laboratories (West Grove, PA) and biotinconjugated rabbit anti-goat antibody (Vector Laboratories, Burlingame, CA). To detect biotin-conjugated secondary antibodies, we used strepavidin PE or allophyocyanin (Jackson ImmunoResearch Laboratories, West Grove, PA).
Brdu Treatment
In Vivo.
We injected mice with Brdu (2 mg/mouse intraperitoneally, every 12 h, Sigma, St. Louis, MO) for 24 and 48 h before sacrifice. Brdu In Vitro.
We incubated freshly isolated blood leukocytes for 6, 12, and 24 h in media containing Brdu (1 mg/ml) and analyzed the Brdu ϩ cells by flow cytometry.
Adoptive Transfer
We isolated BM from MacGreen;MRL-Fas lpr mice 43 and adoptively transferred these EGFP ϩ cells (2 ϫ 10 7 ) by intravenous injection into the tail. We sacrificed these mice after 24 and 48 h and prepared the kidney and blood samples to detect EGFP ϩ cells using flow cytometry as described previously. 41 We adoptively transferred EGFP ϩ BM cells into Csf-1 op/op ;MRL-Fas lpr mice. These mice were then injected with rCSF-1 (50 g/kg body wt) every 12 h, and sacrificed after 24 and 48 h.
BM-Derived Mø
We isolated BM Mo as described previously. 43, 44 When the cultured cells were confluent, we incubated cells for 24 h without CSF-1 to synchronize the cells, before proceeding with specific stimulations.
Proliferation
BM Mo (1 ϫ 10 4 well) were stimulated with mouse CSF-1 (10 ng/ml, Preprotech, Rocky Hill, NJ) for 24 and 48 h. We analyzed proliferation using the MTT colorimetric assay (Roche, Palo Alto, CA) according to the manufacturer's instructions.
Serum, Urine, and Renal Biopsy Samples
Human kidney sections with a confirmed pathologic diagnosis lupus nephritis type III, IV, and V (according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification of lupus nephritis 45 and activity and chronicity index 27, 28 or minimalchange GN and membranous GN were provided by the Department of Pathology, Rush University Medical Center, Chicago, Illinois. Urine and serum samples were collected at the Department of Medicine, Johannes-Gutenberg University Mainz, Germany. Serum and urine samples were stored at Ϫ20°C. The use of the samples was reviewed and approved by the Standing Committee for Clinical Studies of the Johannes-Gutenberg University in adherence to the Declaration of Helsinki. Samples were taken from patients attending the outpatient clinic who fulfilled at least four of the American College of Rheumatology criteria for the classification of systemic lupus erythematosus after informed consent. The characteristics of the patients are summarized in Table 1 . The clinical parameters (C3/C4; dsDNA, creatinine, and proteinuria) were evaluated at the Johannes-Gutenberg University Mainz, Germany. Note that we define C3/C4 levels according to the following criteria: C3 (high Ͼ0.09g/L; low C3Ͻ0.09; and C4 (high C4Ͼ0.01; low C4Ͻ0.01). The control human kidney tissue was taken from uninvolved areas of nephrectomies for malignancy and preimplantation donor kidney biopsies.
Statistical Analysis
The data representing the mean Ϯ SEM were prepared using GraphPad PRISM version 4.0. We used the nonparametric Mann-Whitney U test to evaluate P values. For correlation analysis, we used the Spearman correlation calculation. For statistical evaluation of survival, we used the log rank test.
